A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course

Background: The diagnostic use of biomarkers in body fluids of multiple sclerosis (MS) patients allows the monitoring of different pathophysiological aspects of the disease. We previously reported elevated cerebrospinal fluid (CSF) and serum levels of glial fibrillary acidic protein (GFAP) but not n...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Neurol
Autors principals: Huss, André, Otto, Markus, Senel, Makbule, Ludolph, Albert C., Abdelhak, Ahmed, Tumani, Hayrettin
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Neurology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7378743/
https://ncbi.nlm.nih.gov/pubmed/32765393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.00608
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars